Ioversol

Ioversol
Clinical data
Trade names	Optiray
AHFS/Drugs.com	Multum Consumer Information
Pregnancy; category	AU:B1;
ATC code	V08AB07 ( WHO );
Legal status
Legal status	AU:Unscheduled;
Pharmacokinetic data
Protein binding	Low
Metabolism	None
Elimination half-life	90 min
Excretion	Kidneys
Identifiers
	IUPAC name 1-N,3-N-bis(2,3-dihydroxypropyl)-5-[2-hydroxy-N-(2-hydroxyethyl)acetamido]-2,4,6-triiodobenzene-1,3-dicarboxamide;
CAS Number	87771-40-2 ;
PubChem CID	3741 ;
DrugBank	DB09134 ;
ChemSpider	3610 ;
UNII	N3RIB7X24K ;
KEGG	D01555 ;
ChEMBL	ChEMBL1200614 ;
CompTox Dashboard (EPA)	DTXSID2045521 ;
ECHA InfoCard	100.118.911
Chemical and physical data
Formula	C18H24I3N3O9
Molar mass	807.115 g·mol−1
3D model (JSmol)	Interactive image ;
	SMILES C(CO)N(C1=C(C(=C(C(=C1I)C(=O)NCC(CO)O)I)C(=O)NCC(CO)O)I)C(=O)CO;
	InChI InChI=1S/C18H24I3N3O9/c19-13-11(17(32)22-3-8(29)5-26)14(20)16(24(1-2-25)10(31)7-28)15(21)12(13)18(33)23-4-9(30)6-27/h8-9,25-30H,1-7H2,(H,22,32)(H,23,33) ; Key:AMDBBAQNWSUWGN-UHFFFAOYSA-N ;
	(what is this?) (verify)

Last updated December 27, 2025

Ioversol (INN; trade name Optiray) is an organoiodine compound that is used as a contrast medium. It features both a high iodine content, as well as several hydrophilic groups. It is used in clinical diagnostics including arthrography, angiocardiography and urography.^[1]^[2]

References

↑ "Optiray (ioversol) dosing, indications, interactions, adverse effects, and more". reference.medscape.com. Retrieved 9 January 2021.
↑ Chen Y, Huang X, Huang S, Matchett M (17 February 2011). "13. Fast-in-process method for the determination ioversol and related polar compounds by hydrophilic interactive chromatography". In Wang PG, He W (eds.). Hydrophilic Interaction Liquid Chromatography (HILIC) and Advanced Applications. CRC Press. p. 295-30. ISBN 978-1-4398-0753-8.

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.

[Medscape-1] "Optiray (ioversol) dosing, indications, interactions, adverse effects, and more". reference.medscape.com. Retrieved 9 January 2021.

[Chen-2] Chen Y, Huang X, Huang S, Matchett M (17 February 2011). "13. Fast-in-process method for the determination ioversol and related polar compounds by hydrophilic interactive chromatography". In Wang PG, He W (eds.). Hydrophilic Interaction Liquid Chromatography (HILIC) and Advanced Applications. CRC Press. p. 295-30. ISBN 978-1-4398-0753-8.

[1]

[2]